

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THIS STUDY.....	1
INTENDED AUDIENCE.....	1
SCOPE OF REPORT.....	2
METHODOLOGY.....	2
INFORMATION SOURCES.....	2
ANALYST'S CREDENTIALS.....	2
RELATED BCC REPORTS.....	3
BCC ONLINE SERVICES.....	3
DISCLAIMER.....	3
 CHAPTER TWO: SUMMARY.....	 4
<i>SUMMARY TABLE SALES FOR THE HORMONE REPLACEMENT AND OTHER THERAPIES, THROUGH 2013 (\$ MILLIONS)</i>	 4
<i>SUMMARY FIGURE SALES FOR THE HORMONE REPLACEMENT AND OTHER THERAPIES, 2006-2013 (\$ MILLIONS)</i>	 5
 CHAPTER THREE: OVERVIEW.....	 6
HORMONES.....	6
DEFINITIONS.....	6
Hormone.....	6
Peptide.....	6
Metabolism.....	6
INTRODUCTION.....	6
Classification of Hormones.....	7
Anatomical Source of the Hormone.....	7
Hypothalamic Hormones.....	7
Posterior Pituitary Hormone.....	8
Anterior Pituitary Hormone.....	8
Thyroid Hormones.....	9
Parathyroid Hormones.....	9
Cardiac Hormones.....	10
Adrenal Cortical Hormones.....	10
Adrenal Medullary Hormones.....	11
Kidney Hormones.....	11
Pancreatic Hormones.....	12
Liver Hormones.....	13
Digestive Hormones.....	13
Gonadal Hormones.....	14
Gonadal Hormones (Continued).....	15
Pineal Hormones.....	16
<i>TABLE 1 ANATOMICAL CLASSIFICATION OF HORMONES</i>	 17
Chemical Classification.....	18

Peptide Hormones.....	18
Amine hormones	18
Steroid Hormones	18
<i>TABLE 2 CHEMICAL CLASSIFICATION OF HORMONES</i>	19
HORMONE THERAPY	19
DEFINITION.....	19
CHAPTER FOUR: CLASSIFICATION OF HORMONE THERAPY	20
ESTROGEN THERAPY.....	20
<i>TABLE 3 DRUG PRODUCTS USED IN ESTROGEN THERAPY</i>	20
PROGESTERONE/ESTROGEN THERAPY	21
<i>TABLE 4 DRUG PRODUCTS USED IN ESTROGEN/PROGESTERONE</i>	
<i>COMBINATION THERAPY</i>	21
PROGESTERONE THERAPY	21
<i>TABLE 5 DRUG PRODUCTS USED IN PROGESTERONE THERAPY</i>	21
RECOMBINANT GROWTH HORMONE THERAPY.....	22
<i>TABLE 6 DRUG PRODUCTS USED IN RECOMBINANT GROWTH</i>	
<i>HORMONES</i>	22
THYROID HORMONE THERAPY	22
<i>TABLE 7 DRUG PRODUCTS USED IN THYROID HORMONE</i>	
<i>THERAPY</i>	22
<i>TABLE 7 (CONTINUED)</i>	23
TESTOSTERONE REPLACEMENT THERAPY	23
<i>TABLE 8 DRUG PRODUCTS USED IN TESTOSTERONE</i>	
<i>REPLACEMENT THERAPY</i>	23
SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS).....	23
<i>TABLE 9 DRUG PRODUCTS USED IN SELECTIVE ESTROGEN</i>	
<i>RECEPTOR MODULATORS</i>	24
ANTIESTROGEN THERAPY	24
<i>TABLE 10 DRUG PRODUCTS USED IN ANTIESTROGENS</i>	24
ANTIANDROGEN THERAPY	24
<i>TABLE 11 DRUG PRODUCTS USED IN ANTIANDROGEN THERAPY</i>	25
AROMATASE INHIBITOR THERAPY	25
<i>TABLE 12 DRUG PRODUCTS USED IN AROMATASE INHIBITOR</i>	
<i>THERAPY</i>	25
LUTEINIZING HORMONE-RELEASING HORMONE.....	25
<i>TABLE 13 DRUG PRODUCTS USED AS LUTEINIZING HORMONE-</i>	
<i>RELEASING HORMONE (LH RH)</i>	26
CHAPTER FIVE: HORMONE THERAPY IN VARIOUS CONDITIONS	27
MENOPAUSE.....	27
MENOPAUSE AND HORMONE THERAPY	27
OSTEOPOROSIS	28
OSTEOPOROSIS AND HORMONE THERAPY	28
CANCER.....	29

CANCER AND HORMONE THERAPY.....	30
GROWTH HORMONE DEFICIENCIES.....	30
GROWTH HORMONE DEFICIENCY AND HORMONE THERAPY	31
TURNER'S SYNDROME.....	31
TURNER'S SYNDROME AND HORMONE THERAPY.....	31
KLINFELTER SYNDROME.....	32
KLINFELTER SYNDROME AND HORMONE THERAPY.....	32
THYROID HORMONE DISORDER: HYPOTHYROIDISM	32
HYPOTHYROIDISM AND HORMONE THERAPY	33
MALE HYPOGONADISM.....	33
MALE HYPOGONADISM AND HORMONE THERAPY	34
NOONAN SYNDROME.....	34
NOONAN SYNDROME AND HORMONE THERAPY.....	35
SHORT BOWEL SYNDROME (SBS)	35
SBS AND HORMONE THERAPY	35
PRADER-WILLI SYNDROME.....	36
PRADER-WILLI SYNDROME AND HORMONE THERAPY.....	36
GOITER.....	36
GOITER AND HORMONE THERAPY	37
 CHAPTER SIX: REGULATORY ISSUES.....	 38
NEW DRUG APPROVALS.....	38
<i>TABLE 14 HORMONE THERAPY DRUGS APPROVED BY FDA (2005 TO JUNE 2008)</i>	38
ALL TYPES OF APPROVALS	39
<i>TABLE 15 HORMONE THERAPY ALL TYPES OF APPROVALS BY FDA (2005 TO JUNE 2008)</i>	39
<i>TABLE 15 (CONTINUED)</i>	40
<i>TABLE 15 (CONTINUED)</i>	41
NEW DRUG APPLICATIONS	41
<i>TABLE 16 NEW DRUG APPLICATIONS (2005 TO JUNE 2008)</i>	42
RECALLS AND SAFETY ALERTS	42
<i>TABLE 17 RECALLS AND SAFETY ALERTS (2005 TO JUNE 2008)</i>	43
 CHAPTER SEVEN: INDUSTRY STRUCTURE	 44
ESTROGEN REPLACEMENT THERAPY.....	44
ESTROGEN (ALONE)	44
<i>TABLE 18 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ESTROGEN (ALONE) THERAPY, 2007 (%)</i>	44
<i>FIGURE 1 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ESTROGEN REPLACEMENT THERAPY, 2007 (%)</i>	44
ESTROGEN/PROGESTERONE.....	45

<i>TABLE 19 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR COMBINATION (ESTROGEN/ PROGESTERONE) THERAPY, 2007 (%).....</i>	<i>45</i>
<i>FIGURE 2 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR COMBINATION (ESTROGEN/ PROGESTERONE) THERAPY, 2007 (%).....</i>	<i>45</i>
<i>RECOMBINANT GROWTH HORMONE THERAPY.....</i>	<i>46</i>
<i>TABLE 20 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR RECOMBINANT GROWTH HORMONE THERAPY, 2007 (%).....</i>	<i>46</i>
<i>FIGURE 3 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR RECOMBINANT GROWTH HORMONE THERAPY, 2007 (%).....</i>	<i>46</i>
<i>THYROID HORMONE THERAPY.....</i>	<i>47</i>
<i>TABLE 21 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR THYROID HORMONE THERAPY, 2007 (%).....</i>	<i>47</i>
<i>FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR THYROID HORMONE THERAPY, 2007 (%).....</i>	<i>47</i>
<i>TESTOSTERONE HORMONE THERAPY.....</i>	<i>48</i>
<i>TABLE 22 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TESTOSTERONE HORMONE THERAPY, 2007 (%).....</i>	<i>48</i>
<i>FIGURE 5 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TESTOSTERONE HORMONE THERAPY, 2007 (%).....</i>	<i>48</i>
<i>ANTIESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERM).....</i>	<i>49</i>
<i>TABLE 23 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2007 (%).....</i>	<i>49</i>
<i>FIGURE 6 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2007 (%).....</i>	<i>49</i>
<i>ANTIANDROGENS.....</i>	<i>50</i>
<i>TABLE 24 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIANDROGENS, 2007 (%).....</i>	<i>50</i>
<i>FIGURE 7 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIANDROGENS, 2007 (%).....</i>	<i>50</i>
<i>AROMATASE INHIBITORS.....</i>	<i>51</i>
<i>TABLE 25 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR AROMATASE INHIBITORS, 2007 (%).....</i>	<i>51</i>
<i>FIGURE 8 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR AROMATASE INHIBITORS, 2007 (%).....</i>	<i>51</i>
<i>LUTEINIZING HORMONE RELEASING HORMONE (LHRH) AGONISTS.....</i>	<i>52</i>
<i>TABLE 26 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR LH RH AGONISTS, 2007 (%).....</i>	<i>52</i>

	<i>FIGURE 9 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR LH RH AGONISTS, 2007 (%)</i>	52
CHAPTER EIGHT: DEMAND AND USE	53
KEY MARKET RESTRAINTS	53
COMPETITION	53
PATENT EXPIRATION	54
<i>TABLE 27 SIGNIFICANT PATENT EXPIRIES</i>	54
COST OF HRT DRUGS	54
LOW AWARENESS	55
KEY MARKET DRIVERS	55
NEW DRUG DELIVERY TECHNOLOGIES	55
GROWING AWARENESS	55
AGING OF THE POPULATION	55
RETURNING CONFIDENCE IN HRT	56
BENEFITS OF HRT OVER NON-HORMONAL DRUGS	56
LIFE EXPECTANCY	56
DTC (DIRECT TO CONSUMER) ADVERTISING	56
STRATEGIES OF MANUFACTURERS	56
Strategies of Manufacturers (Continued)	57
CHAPTER NINE: MARKET ANALYSIS	58
MARKET SIZE	58
<i>TABLE 28 WORLDWIDE SALES OF HORMONE THERAPIES, THROUGH 2013 (\$ MILLIONS)</i>	58	
<i>FIGURE 10 WORLDWIDE SALES OF HORMONE THERAPIES, 2006- 2013 (\$ MILLIONS)</i>	59	
<i>TABLE 29 WORLDWIDE SHARE OF HORMONE THERAPIES, 2007</i>	60	
<i>FIGURE 11 WORLDWIDE SHARE OF HORMONE THERAPIES, 2007 (%)</i>	60	
ESTROGEN REPLACEMENT THERAPY	61
Market Outlook	61
ESTROGEN	61
Market Size	61
<i>TABLE 30 GLOBAL SALES OF ESTROGEN (ALONE) THERAPY, THROUGH 2013 (\$ MILLIONS)</i>	61	
<i>FIGURE 12 WORLDWIDE SALES OF ESTROGEN (ALONE) THERAPY, 2006-2013 (\$ MILLIONS)</i>	62	
COMBINATION THERAPY (ESTROGEN/ PROGESTERONE)	62
Market Size	62
<i>TABLE 31 GLOBAL SALES OF COMBINATION THERAPY (ESTROGEN/PROGESTERONE), THROUGH 2013 (\$ MILLIONS)</i>	62	
<i>FIGURE 13 WORLDWIDE SALES OF COMBINATION THERAPY (ESTROGEN/PROGESTERONE), 2006-2013 (\$ MILLIONS)</i>	63	
RECOMBINANT GROWTH HORMONE THERAPY	63

Market Outlook.....	63
Market Size.....	64
<i>TABLE 32 GLOBAL SALES OF RECOBINANT GROWTH HORMONE THERAPY THROUGH 2013 (\$ MILLIONS)</i>	64
<i>FIGURE 14 WORLDWIDE SALES OF RECOMBINANT GROWTH HORMONE THERAPY, 2006-2013 (\$ MILLIONS)</i>	64
THYROID HORMONE THERAPY	65
Market Outlook.....	65
Market Size.....	65
<i>TABLE 33 GLOBAL SALES OF THYROID HORMONE THERAPY, THROUGH 2013 (\$ MILLIONS)</i>	65
<i>FIGURE 15 WORLDWIDE SALES OF THYROID HORMONE THERAPY, 2006-2013 (\$ MILLIONS)</i>	66
TESTOSTERONE HORMONE THERAPY	67
Market Outlook.....	67
Market Size.....	67
<i>TABLE 34 GLOBAL SALES OF TESTOSTERONE HORMONE THERAPY, THROUGH 2013 (\$ MILLIONS)</i>	67
<i>FIGURE 16 WORLDWIDE SALES OF TESTOSTERONE HORMONE THERAPY, 2006-2013 (\$ MILLIONS)</i>	68
ANTIESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERM).....	69
Market Outlook.....	69
Market Size.....	69
<i>TABLE 35 GLOBAL SALES OF ANTIESTROGEN AND SELECTIVE ESTROGEN RECEPTOR MODULATORS, THROUGH 2013 (\$ MILLIONS)</i>	69
<i>FIGURE 17 WORLDWIDE SALES OF ANTIESTROGEN AND SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2006-2013 (\$ MILLIONS)</i>	70
ANTIANDROGEN THERAPY	70
Market Outlook.....	70
Market Size.....	71
<i>TABLE 36 GLOBAL SALES OF ANTIANDROGEN THERAPY, THROUGH 2013 (\$ MILLIONS)</i>	71
<i>FIGURE 18 WORLDWIDE SALES OF ANTIANDROGEN THERAPY, 2006-2013 (\$ MILLIONS)</i>	71
AROMATASE INHIBITORS	72
Market Outlook.....	72
Market Size.....	73
<i>TABLE 37 GLOBAL SALES OF AROMATASE INHIBITORS, THROUGH 2013 (\$ MILLIONS)</i>	73
<i>FIGURE 19 WORLDWIDE SALES OF AROMATASE INHIBITORS, 2006-2013 (\$ MILLIONS)</i>	73

LUTEINIZING HORMONE-RELEASING HORMONE (LH RH)	
AGONISTS.....	74
Market Outlook.....	74
Market Size.....	74
TABLE 38 GLOBAL SALES OF LH RH AGONISTS, THROUGH 2013 (\$	
MILLIONS).....	74
FIGURE 20 WORLDWIDE SALES OF LH RH AGONIST, 2006-2013 (\$	
MILLIONS).....	75
New Developments	75
TABLE 39 CLINICAL TRIALS IN THE ESTROGEN REPLACEMENT	
THERAPY	76
TABLE 39 (CONTINUED).....	77
TABLE 40 CLINICAL TRIALS IN THE PROGESTERONE THERAPY	77
TABLE 40 (CONTINUED).....	78
TABLE 41 CLINICAL TRIALS IN THYROID HORMONE THERAPY	78
TABLE 42 CLINICAL TRIALS IN TESTOSTERONE REPLACEMENT	
THERAPY	79
TABLE 42 (CONTINUED).....	80
TABLE 43 CLINICAL TRIALS IN RECOMBINANT GROWTH	
HORMONE	81
TABLE 43 (CONTINUED).....	82
TABLE 44 CLINICAL TRIALS IN ANTIESTROGEN THERAPY	83
TABLE 44 (CONTINUED).....	84
TABLE 44 (CONTINUED).....	85
TABLE 45 CLINICAL TRIALS IN ESTROGEN RECEPTOR	
MODULATORS	85
TABLE 46 CLINICAL TRIALS IN ANTIANDROGEN THERAPY.....	86
TABLE 47 CLINICAL TRIALS IN AROMATASE INHIBITORS	87
TABLE 48 CLINICAL TRIALS IN LH RH AGONISTS	88
CHAPTER TEN: MARKET BY DISEASE TYPE.....	89
TABLE 49 GLOBAL SALES OF HORMONE THERAPY BY TYPE OF	
DISEASE, THROUGH 2013 (\$ MILLIONS).....	89
FIGURE 21 GLOBAL SALES OF HORMONE THERAPY BY TYPE OF	
DISEASE, 2006-2013 (\$ MILLIONS)	90
TABLE 50 MARKET SHARE OF VARIOUS TYPES OF DISEASES, 2007	
(%).....	90
FIGURE 22 MARKET SHARE OF VARIOUS TYPES OF DISEASES,	
2007 (%).....	91
MENOPAUSE	91
TABLE 51 GLOBAL SALES OF HRT IN MENOPAUSE MARKET,	
THROUGH 2013 (\$ MILLIONS).....	92
FIGURE 23 GLOBAL SALES OF HRT IN MENOPAUSE MARKET,	
2006-2013 (\$ MILLIONS).....	92
OSTEOPOROSIS	93

<i>TABLE 52 GLOBAL SALES OF HRT IN OSTEOPOROSIS MARKET, THROUGH 2013 (\$ MILLIONS)</i>	93
<i>FIGURE 24 GLOBAL SALES OF HRT IN OSTEOPOROSIS MARKET, 2006-2013 (\$ MILLIONS)</i>	93
HYPOTHYROIDISM	94
<i>TABLE 53 GLOBAL SALES OF HRT IN HYPOTHYROID MARKET, THROUGH 2013 (\$ MILLIONS)</i>	94
<i>FIGURE 25 GLOBAL SALES OF HRT IN HYPOTHYROID MARKET, 2006-2013 (\$ MILLIONS)</i>	95
MALE HYPOGONADISM	95
<i>TABLE 54 GLOBAL SALES OF HRT IN THE MALE HYPOGONADISM MARKET, THROUGH 2013 (\$ MILLIONS)</i>	95
<i>FIGURE 26 GLOBAL SALES OF HRT IN THE MALE HYPOGINADISM MARKET, 2006-2013 (\$ MILLIONS)</i>	96
KLINEFELTER SYNDROME.....	96
<i>TABLE 55 GLOBAL SALES OF HRT IN KLINEFELTER SYNDROME MARKET, THROUGH 2013 (\$ MILLIONS)</i>	97
<i>FIGURE 27 GLOBAL SALES OF HRT IN KLINEFELTER SYNDROME MARKET, 2006-2013 (\$ MILLIONS)</i>	97
TURNER'S SYNDROME.....	98
<i>TABLE 56 GLOBAL SALES OF HRT IN TURNER'S SYNDROME MARKET, THROUGH 2013 (\$ MILLIONS)</i>	98
<i>FIGURE 28 GLOBAL SALES OF HRT IN TURNER'S SYNDROME MARKET, 2006-2013 (\$ MILLIONS)</i>	99
GROWTH HORMONE DEFICIENCY.....	99
<i>TABLE 57 GLOBAL SALES OF HRT IN GROWTH HORMONE DEFICIENCY MARKET, THROUGH 2013 (\$ MILLIONS)</i>	100
<i>FIGURE 29 GLOBAL SALES OF HRT IN GROWTH HORMONE DEFECIENCY MARKET, 2006-2013 (\$ MILLIONS)</i>	101
CANCER.....	101
<i>TABLE 58 GLOBAL SALES OF HRT IN CANCER MARKE, THROUGH 2013 (\$ MILLIONS)</i>	102
<i>FIGURE 30 GLOBAL SALES OF HRT IN CANCER MARKET, 2006-2013 (\$ MILLIONS)</i>	102
CHAPTER ELEVEN: PATENT ANALYSIS	103
TOTAL PATENTS	103
PATENTS BY YEAR	103
<i>TABLE 59 TOTAL NUMBER OF PATENTS IN EACH YEAR, 2005–2008</i>	103
<i>FIGURE 31 NUMBER OF PATENTS, 2005-2008</i>	104
PATENTS BY TYPE	104
<i>TABLE 60 NUMBER OF PATENTS BY TYPE, 2005-2008</i>	104
<i>FIGURE 32 NUMBER OF PATENTS BY TYPE, 2005-2008</i>	105
<i>FIGURE 33 NUMBER OF PATENTS, SHARE BY TYPE OF HORMONE, 2005-2008 (%)</i>	105

<i>FIGURE 33 (CONTINUED)</i>	106
PATENTS BY COUNTRY	106
<i>TABLE 61 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2008</i>	106
<i>FIGURE 34 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2008</i>	107
PATENTS BY COMPANY	107
<i>TABLE 62 NUMBER OF PATENTS BY COMPANY, 2005-2008</i>	108
<i>FIGURE 35 NUMBER OF PATENTS BY COMPANY, 2005-2008</i>	109
PATENTS BY ASSIGNEE	109
<i>TABLE 63 NUMBER OF PATENTS BY ASSIGNEE TYPE, 2005–2008</i>	110
<i>FIGURE 36 NUMBER OF PATENTS BY ASSIGNEE, 2005–2008</i>	110

CHAPTER TWELVE: CURRENT AND FUTURE HORMONE REPLACEMENT THERAPY AND “OTHER” HORMONE THERAPY MARKET	111
<i>TABLE 64 LEADING BRANDED DRUGS IN VARIOUS HORMONE THERAPIES</i>	111
CURRENT AND FUTURE HORMONE...(CONTINUED).....	112

CHAPTER THIRTEEN: COMPANY PROFILES	113
ABBOTT LABORATORIES INC.....	113
ACRUX LIMITED	113
ASCEND THERAPEUTICS	114
ASTRAZENECA PLC	114
AUXILIUM PHARMACEUTICALS, INC.....	115
BARR PHARMACEUTICALS, INC.	115
BAYER SCHERING PHARMA AG.....	116
BIOSANTE PHARMACEUTICALS.....	116
CANGENE CORPORATION.....	117
COLUMBIA LABORATORIES, INC.	117
ELI LILLY & CO.....	118
EMD SERONO, INC.....	118
FERRING PHARMACEUTICALS	118
GALEN LTD.....	119
GENENTECH	119
GENESCIENCE PHARMACEUTICALS INC.	120
IMPAX LABORATORIES, INC.....	120
INDEVUS PHARMECEUTICALS, INC.....	121
IPSEN SA.....	121
JHP PHARMACEUTICALS	122
KING PHARMACEUTICALS, INC.	122
KV PHARMACEUTICALS	123
MYLAN, INC.....	123
NOVARTIS	124
NOVO NORDISK.....	124
NYCOMED U.S.....	125

ORION CORPORATION	125
PADDOCK LABORATORIES, INC.	126
PAR PHARMACEUTICAL COMPANIES, INC.	126
PFIZER INC.	127
SANOFI AVENTIS	127
SOLVAY PHARMACEUTICALS	128
SYNERX PHARMA.....	128
UNIGENE LABORATORIES, INC.....	128
UNIMED PHARMACEUTICALS, INC.	129
WARNER CHILCOTT	129
WATSON LABS	130
WYETH	130
APPENDIX.....	131
ABBREVIATIONS	131
ABBREVIATIONS (CONTINUED).....	132